Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash from Financing Activities (2016 - 2025)

Catalyst Pharmaceuticals' Cash from Financing Activities history spans 15 years, with the latest figure at -$25.6 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 677.04% year-over-year to -$25.6 million; the TTM value through Dec 2025 reached -$17.0 million, down 112.08%, while the annual FY2025 figure was -$17.0 million, 112.08% down from the prior year.
  • Cash from Financing Activities reached -$25.6 million in Q4 2025 per CPRX's latest filing, down from $4.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $141.0 million in Q1 2024 to a low of -$25.6 million in Q4 2025.
  • Average Cash from Financing Activities over 5 years is $5.3 million, with a median of -$32500.0 recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: crashed 10397.22% in 2021, then soared 94563.76% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$2.5 million in 2021, then surged by 189.19% to $2.3 million in 2022, then crashed by 129.52% to -$665000.0 in 2023, then soared by 766.62% to $4.4 million in 2024, then plummeted by 677.04% to -$25.6 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Cash from Financing Activities are -$25.6 million (Q4 2025), $4.7 million (Q3 2025), and $872000.0 (Q2 2025).